Tid Tittel Kategori Vedlegg
09.11.2026
07:00
 Lytix Biopharma to Present NeoLIPA Phase II Results in Late-Breaking Oral Presentation at ESMO IO 2026 -
1
09.11.2026
07:00
 Lytix Biopharma presenterer late-breaking fase II-resultater fra NeoLIPA på ESMO IO 2026 -
1
06.11.2026
13:09
 Lytix Biopharma: Invitation to the Q3 2026 Results Presentation - -
05.11.2026
07:00
 Research Council of Norway awards Lytix Biopharma NOK 12 million to extend its oncolytic platform to deep-seated tumors -
1
03.11.2026
07:00
 Lytix Biopharma kunngjør at ruxotemitide i kombinasjon med pembrolizumab har nådd det primære endepunktet i fase II-studien NeoLIPA i pasienter med operabelt melanom INFORMASJON INF
1
03.11.2026
07:00
 Lytix Biopharma announces ruxotemitide plus pembrolizumab meets primary endpoint in Phase II NeoLIPA study in resectable melanoma INFORMASJON INF
1
03.09.2026
15:02
 Lytix Biopharma ASA: Grant of share options to management and key personnel INSIDEHANDEL INS
1
02.09.2026
22:01
 Lytix Biopharma ASA: Mandatory notification of trade by primary insider INSIDEHANDEL INS
1
27.08.2026
07:00
 Lytix Biopharma Q2 2026: FDA Feedback Clears Path to Registrational Phase III Trial for Ruxotemitide (LTX-315) in Patients with Resectable High-Risk Melanoma, Marking Defining Milestone RAPPORT RAP
2
27.08.2026
06:55
 FDA Feedback Clears Path to Registrational Phase III Trial for Ruxotemitide (LTX-315) in Patients with Resectable High-Risk Melanoma - -
26.08.2026
17:01
 Lytix to Partner with Leading Investigator on ALETTA Study Testing Ruxotemitide in Combination with Ipilimumab and Nivolumab in Early-stage Resectable Melanoma - -
21.08.2026
07:30
 Lytix Biopharma: Invitation to the Q2 2026 Results Presentation - -
18.08.2026
10:30
 Lytix Biopharma Strengthens Business Development Leadership with Appointment of Timothy Herpin as Chief Business Officer - -
23.07.2026
14:15
 Lytix Biopharma ASA: Grant of share options to management and key personnel INSIDEHANDEL INS
1
01.06.2026
07:05
 Lytix Biopharma Reports Phase II Data in Melanoma and Triple-Negative Breast Cancer for Ruxotemitide (LTX-315) in Combination with Pembrolizumab - -
21.05.2026
07:00
 Lytix Biopharma Q1 2026: Clinical Development Priorities On Track as Registrational Path Planning Advances RAPPORT RAP
1
15.05.2026
10:16
 Lytix Biopharma: Invitation to the Q1 2026 Results Presentation - -
06.05.2026
07:00
 New Phase II Study Data from Lytix Biopharma’s Partner Verrica Pharmaceuticals to be Presented at SID 2026 Highlight Potential Abscopal Effects of Ruxotemitide in Basal Cell Carcinoma - -
21.04.2026
16:00
 Lytix Biopharma ASA to Showcase Promising Phase II Results for Ruxotemitide Combination Therapy at ASCO 2026 - -
21.04.2026
07:00
 Lytix Biopharma ASA Reports Promising Final Phase II Results for Ruxotemitide (LTX-315) in Combination with Pembrolizumab in PD-1/PD-L1 Refractory Advanced Melanoma -
1
16.04.2026
23:18
 Lytix Biopharma ASA – Conversion to public limited liability company and name change registered - -
14.04.2026
17:07
 Lytix Biopharma AS: Minutes from Annual General Meeting -
1
09.04.2026
20:52
 Lytix Biopharma AS: MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER - GRANT OF SHARE OPTIONS INSIDEHANDEL INS
1
07.04.2026
07:00
 Lytix Biopharma Appoints Renée Christine Amundsen as Chief Operating Officer to Support Next Phase of Growth -
1
25.03.2026
09:14
 Lytix Biopharma AS: Notice of Annual General Meeting on 14 April 2026 -
1